Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell... ORIGINAL ARTICLE Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy Sigve Andersen, MD,*† Tom Donnem, MD,*† Samer Al-Saad, MD,‡§ Khalid Al-Shibli, MD,‡ Lill-Tove Busund, MD, PhD,‡§ and Roy M. Bremnes, MD, PhD*† ung cancer is the leading cause of cancer-related deaths Introduction: Protein expressions of angiogenic markers provide Lworld-wide and non-small cell lung cancer (NSCLC) prognostic information on patients with non-small cell lung cancer accounts for approximately 80% of all lung cancer cases. (NSCLC). Both expression and its prognostic impact may be asso- Despite extensive efforts over the last decades, current treat- ciated with patient selection. Data addressing the prognostic rele- ment modalities have only marginally improved survival vance of angiogenic marker expression in NSCLC patients treated rates. Angiogenesis is considered a hallmark of cancer de- with postoperative radiotherapy (PORT) is warranted. velopment as tumor growth requires neovascularization to Methods: In 55 patients with stage I-IIIA NSCLC administered grow beyond a diameter of 2 mm. Angiogenesis is facilitated PORT between 1990 and 2005, we have reviewed the clinicopath- through secretion of ligands acting in an autocrine and paracrine ological variables and investigated the expression of angiogenic manner http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Journal of Thoracic Oncology , Volume 4 (4) – Apr 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/angiogenic-markers-show-high-prognostic-impact-on-survival-in-KV5WkK6h6U

References (48)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181991d18
pmid
19204576
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy Sigve Andersen, MD,*† Tom Donnem, MD,*† Samer Al-Saad, MD,‡§ Khalid Al-Shibli, MD,‡ Lill-Tove Busund, MD, PhD,‡§ and Roy M. Bremnes, MD, PhD*† ung cancer is the leading cause of cancer-related deaths Introduction: Protein expressions of angiogenic markers provide Lworld-wide and non-small cell lung cancer (NSCLC) prognostic information on patients with non-small cell lung cancer accounts for approximately 80% of all lung cancer cases. (NSCLC). Both expression and its prognostic impact may be asso- Despite extensive efforts over the last decades, current treat- ciated with patient selection. Data addressing the prognostic rele- ment modalities have only marginally improved survival vance of angiogenic marker expression in NSCLC patients treated rates. Angiogenesis is considered a hallmark of cancer de- with postoperative radiotherapy (PORT) is warranted. velopment as tumor growth requires neovascularization to Methods: In 55 patients with stage I-IIIA NSCLC administered grow beyond a diameter of 2 mm. Angiogenesis is facilitated PORT between 1990 and 2005, we have reviewed the clinicopath- through secretion of ligands acting in an autocrine and paracrine ological variables and investigated the expression of angiogenic manner

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Apr 1, 2009

There are no references for this article.